Data gathered: January 30
AI Stock Analysis - Genmab A/S (GMAB)
Analysis generated January 16, 2025. Powered by Chat GPT.
Genmab A S is a biotechnology company that specializes in the creation and development of antibody treatments for cancer and other diseases. Headquartered in Copenhagen, Denmark, Genmab has a strong reputation for innovation and research within the pharmaceutical sector. The company’s primary products focus on oncology and immunotherapy, and Genmab has established partnerships with several leading global pharmaceutical companies.
Stock Alerts - Genmab A/S (GMAB)
 |
Genmab A/S | January 28 Price is down by -7.9% in the last 24h. |
|
Genmab A/S | January 21 Business Outlook among employees is down by 3.3% over the last month. |
|
Genmab A/S | January 16 Price is up by 5% in the last 24h. |
|
Genmab A/S | January 15 Price is down by -6.2% in the last 24h. |
Alternative Data for Genmab A/S
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 76 | Sign up | Sign up | Sign up |
| Sentiment | 93 | Sign up | Sign up | Sign up |
| Webpage traffic | 38,000 | Sign up | Sign up | Sign up |
| Employee Rating | 88 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 834 | Sign up | Sign up | Sign up |
| Twitter Followers | 8,072 | Sign up | Sign up | Sign up |
| Twitter Mentions | 25 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 403 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 89 | Sign up | Sign up | Sign up |
| Linkedin Employees | 2,627 | Sign up | Sign up | Sign up |
About Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.
| Price | $19.81 |
| Target Price | Sign up |
| Volume | 1,270,000 |
| Market Cap | $12.4B |
| Year Range | $19.58 - $28.83 |
| Dividend Yield | 0% |
| PE Ratio | 19.39 |
| Analyst Rating | 43% buy |
| Earnings Date | February 12 '25 |
| Industry | Biotechnology |
In the news
 |
High Growth Tech Stocks To Watch In January 2025January 6 - Yahoo |
 |
Genmab to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 3 - Yahoo |
 |
PeptiDream: Opulent Dream Now A RealityDecember 18 - SeekingAlpha |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 5.54B | 273M | 5.27B | 1.27B | 1.85B | 0.290 |
| Q2 '24 | 5.4B | 190M | 5.21B | 1.41B | 2.15B | 0.310 |
| Q1 '24 | 4.14B | 185M | 3.96B | 1.33B | 861M | 0.290 |
| Q4 '23 | 4.68B | 126M | 4.55B | 640M | 1.73B | 0.140 |
| Q3 '23 | 4.74B | 100M | 4.64B | 2.13B | 1.96B | 0.470 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Josh Gottheimer |
Jan 15, 25 | Sell | $1K - $15K |
| Josh Gottheimer |
Aug 15, 24 | Buy | $1K - $15K |
| Josh Gottheimer |
Jul 9, 24 | Sell | $1K - $15K |
Read more about Genmab A/S (GMAB) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Genmab A/S?
The Market Cap of Genmab A/S is $12.4B.
What is Genmab A/S's PE Ratio?
As of today, Genmab A/S's PE (Price to Earnings) ratio is 19.39.
When does Genmab A/S report earnings?
Genmab A/S will report its next earnings on February 12 '25.
What is the current stock price of Genmab A/S?
Currently, the price of one share of Genmab A/S stock is $19.81.
How can I analyze the GMAB stock price chart for investment decisions?
The GMAB stock price chart above provides a comprehensive visual representation of Genmab A/S's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Genmab A/S shares. Our platform offers an up-to-date GMAB stock price chart, along with technical data analysis and alternative data insights.
Does GMAB offer dividends to its shareholders?
As of our latest update, Genmab A/S (GMAB) does not offer dividends to its shareholders. Investors interested in Genmab A/S should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Genmab A/S?
Some of the similar stocks of Genmab A/S are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.